Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by $1.57

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.66, $1.57 better than the analyst estimate of $1.09. Revenue for the quarter came in at $97.8 million versus the consensus estimate of $93.19 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval